[go: up one dir, main page]

AR131211A1 - Derivados de aril- y heteroaril-sulfonamida como moduladores de ccr8 - Google Patents

Derivados de aril- y heteroaril-sulfonamida como moduladores de ccr8

Info

Publication number
AR131211A1
AR131211A1 ARP230103232A ARP230103232A AR131211A1 AR 131211 A1 AR131211 A1 AR 131211A1 AR P230103232 A ARP230103232 A AR P230103232A AR P230103232 A ARP230103232 A AR P230103232A AR 131211 A1 AR131211 A1 AR 131211A1
Authority
AR
Argentina
Prior art keywords
ccr8
modulators
heteroaryl
aryl
sulfonamide derivatives
Prior art date
Application number
ARP230103232A
Other languages
English (en)
Inventor
Hamed Aissaoui
Oliver Corminboeuf
Stefan Diethelm
Lubos Remen
Sylvia Richard-Bildstein
Original Assignee
Idorsia Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Idorsia Pharmaceuticals Ltd filed Critical Idorsia Pharmaceuticals Ltd
Publication of AR131211A1 publication Critical patent/AR131211A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/02—Local antiseptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención se refiere un compuestos de fórmula (1), su síntesis y uso como moduladores del receptor CCR8 en medicina.
ARP230103232A 2022-11-30 2023-11-29 Derivados de aril- y heteroaril-sulfonamida como moduladores de ccr8 AR131211A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP2022083811 2022-11-30

Publications (1)

Publication Number Publication Date
AR131211A1 true AR131211A1 (es) 2025-02-26

Family

ID=89076058

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP230103232A AR131211A1 (es) 2022-11-30 2023-11-29 Derivados de aril- y heteroaril-sulfonamida como moduladores de ccr8

Country Status (3)

Country Link
AR (1) AR131211A1 (es)
TW (1) TW202430180A (es)
WO (1) WO2024115549A1 (es)

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002363236A1 (en) 2001-10-30 2003-05-12 Millennium Pharmaceuticals, Inc. Compounds, pharmaceutical compositions and methods of use therefor
AU2003275480A1 (en) 2002-10-07 2004-05-04 Smithkline Beecham Corporation Compounds
AU2003303483A1 (en) 2002-12-23 2004-07-22 Millennium Pharmaceuticals, Inc. Ccr8 inhibitors
TW200510311A (en) 2002-12-23 2005-03-16 Millennium Pharm Inc CCr8 inhibitors
WO2004073619A2 (en) 2003-02-14 2004-09-02 Smithkline Beecham Corporation Ccr8 antagonists
WO2004074438A2 (en) 2003-02-14 2004-09-02 Smithkline Beecham Corporation Ccr8 antagonists
SE0302811D0 (sv) 2003-10-23 2003-10-23 Astrazeneca Ab Novel compounds
JP2008534677A (ja) 2005-04-04 2008-08-28 アストラゼネカ・アクチエボラーグ 新規ジアザスピロアルカン類およびｃｃｒ８介在疾患の処置のためのそれらの使用
WO2006107253A1 (en) 2005-04-04 2006-10-12 Astrazeneca Ab Novel diazaspiroalkanes and their use for treatment of ccr8 mediated diseases
EP1869045A1 (en) 2005-04-04 2007-12-26 AstraZeneca AB Novel diazaspiroalkanes and their use for treatment of ccr8 mediated diseases
TW200800999A (en) 2005-09-06 2008-01-01 Astrazeneca Ab Novel compounds
WO2008099165A1 (en) 2007-02-15 2008-08-21 Astrazeneca Ab Piperidine derivatives and their use for treatment of ccr8 mediated diseases
WO2013131010A2 (en) 2012-03-02 2013-09-06 Icahn School Of Medicine At Mount Sinai Function of chemokine receptor ccr8 in melanoma metastasis
KR102276644B1 (ko) 2013-09-04 2021-07-13 브리스톨-마이어스 스큅 컴퍼니 면역조절제로서 유용한 화합물
HRP20181052T1 (hr) 2013-09-06 2018-09-07 Aurigene Discovery Technologies Limited Derivati 1,2,4-oksadiazola kao imunomodulatori
WO2015044900A1 (en) 2013-09-27 2015-04-02 Aurigene Discovery Technologies Limited Therapeutic immunomodulating compounds
CN115989223B (zh) 2020-07-03 2024-09-20 南京艾美斐生物医药科技有限公司 使用CCR8抑制剂靶向Tregs的方法和组合物

Also Published As

Publication number Publication date
TW202430180A (zh) 2024-08-01
WO2024115549A1 (en) 2024-06-06

Similar Documents

Publication Publication Date Title
ECSP20053845A (es) Macrociclos como moduladores del regulador de conductancia transmembrana de la fibrosis quística, composiciones farmacéuticas de estos, su uso en el tratamiento de la fibrosis quística y procesos para elaborarlos
ECSP056019A (es) 2,4-di(fenilamino)pirimidinas útiles en el tratamiento de enfermedades neoplásicas, trastornos inflamatorios y del sistema inmune
MX2022011354A (es) Compuestos de pirimidina fusionados como moduladores de kcc2.
CL2019003274A1 (es) Derivados de pirimidina como moduladores del receptor de pge2.
AR132703A1 (es) Compuestos tricíclicos y usos de los mismos
CL2022003646A1 (es) Derivados de amidopirimidona
MX2023004920A (es) Compuestos inhibidores de la proteina 6 del linfoma de linfocitos b (bcl6).
ECSP11011470A (es) Nuevos derivados de pirimidina y sus usos en el tratamiento del cáncer y otras enfermedades
CO2022016899A2 (es) Moduladores de il-17a
MY208400A (en) Benzimidazole derivatives as modulators of retinoid-related orphan receptor gamma (ror) and pharmaceutical uses thereof
UY30572A1 (es) N-(1-ftalazin-1-il-piperidin-4-il)-amidas como moduladores del receptor ep2
MX2022002053A (es) Conjugados de il-15 y sus usos.
CR20190567A (es) Derivados de indol n-sustituidos
CO2022018636A2 (es) Moduladores de il-17a
CY1122731T1 (el) Διαμορφωτες υποδοχεα οιστρογονων
CL2021003228A1 (es) Compuestos tricíclicos y su uso
CY1113146T1 (el) 11-φωσφο-στεροειδη παραγωγα ως τροποποιητες του υποδοχεα προγεστερονης
CL2017002498A1 (es) Piridopirimidinonas y su uso como modulares del receptor nmda
CL2021003348A1 (es) Derivados de piridin–3–ilo.
CO2024010803A2 (es) Compuestos de tienopirrolotriazina, su preparación y su uso terapéutico
DOP2021000103A (es) Pirazoles como moduladores de hemoglobina
MX2021012543A (es) Compuestos de indoles quirales y su uso.
AR131211A1 (es) Derivados de aril- y heteroaril-sulfonamida como moduladores de ccr8
CL2025001109A1 (es) Compuestos derivados de pirazina-carboxamida.
GEAP202416510A (en) BICYCLIC AMINE DERIVATIVES AS GABAA α5 RECEPTOR MODULATORS

Legal Events

Date Code Title Description
FB Suspension of granting procedure